Get the Stockscreener App
212.26
2.02%
4.20
After Hours:
224.84
12.58
+5.93%
Jazz Pharmaceuticals Plc stock is traded at $212.26, with a volume of 1.21M.
It is up +2.02% in the last 24 hours and up +13.54% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$208.06
Open:
$209.71
24h Volume:
1.21M
Relative Volume:
1.29
Market Cap:
$13.32B
Revenue:
$4.27B
Net Income/Loss:
$-356.15M
P/E Ratio:
-35.55
EPS:
-5.9702
Net Cash Flow:
$1.19B
1W Performance:
+4.06%
1M Performance:
+13.54%
6M Performance:
+54.69%
1Y Performance:
+79.59%
1-Day Range:
$208.41
$212.57
1-Week Range:
$198.68
$212.57
52-Week Range:
$97.50
$212.57
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
212.26 | 13.05B | 4.27B | -356.15M | 1.19B | -5.9702 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Earnings call transcript: Jazz Pharmaceuticals Q1 2026 earnings beat expectations By Investing.com - Investing.com Canada
Jazz Pharmaceuticals plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:JAZZ) 2026-05-05 - Seeking Alpha
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
Jazz Pharmaceuticals surges on earnings beat, strong revenue By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals surges on earnings beat, strong revenue - Investing.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat - ChartMill
Jazz: Q1 Earnings Snapshot - wwltv.com
(JAZZ) Jazz Pharmaceuticals Expects Full Year 2026 Revenue Range $4.25B$4.50B, vs. FactSet Est of $4.44B - marketscreener.com
Bruce Cozadd sells 6,000 Jazz (NASDAQ: JAZZ) shares under 10b5-1 plan - Stock Titan
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Reports Q1 Revenue $1.07B, vs. FactSet Est of $978.5M - marketscreener.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales - Yahoo Finance
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q1 Adjusted EPS $6.34 per Share - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) swings to Q1 2026 profit on PRV sale - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) posts 19% Q1 revenue growth - Stock Titan
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results - PR Newswire
All eyes on Jazz Pharmaceuticals earnings as FDA decision nears By Investing.com - Investing.com Canada
All eyes on Jazz Pharmaceuticals earnings as FDA decision nears - Investing.com
MSN Money - MSN
Jazz Pharmaceuticals stock hits all-time high at 207.49 USD By Investing.com - Investing.com India
Jazz Pharmaceuticals stock hits all-time high at 207.49 USD - Investing.com
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone - simplywall.st
Jazz Pharmaceuticals (NASDAQ: JAZZ) reports two 6,000-share Rule 144 sales - Stock Titan
JAZZ Forecast, Price Target & Analyst Ratings | JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) - ChartMill
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Sees Significant Decline in Short Interest - MarketBeat
Vanguard Capital Management reports 5.04% stake in Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan
Will Ziihera’s Priority Review in First-Line HER2-Positive Gastric Cancer Shift Jazz Pharmaceuticals’ (JAZZ) Narrative? - simplywall.st
Pictet Asset Management Holding SA Sells 33,547 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
M&T Bank Corp Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
US Cannabis Market Report Analysis Report 2026-2034 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora Cannabis, Jazz Pharma, GTI, Trulieve, Cresco Labs, Organigram Global, TerrAscend - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Market Driver Insights: The Impact of Recent Developments on the Erwinaze/Spectrila Market - openPR.com
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer By Investing.com - Investing.com South Africa
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer - Investing.com UK
Wells Fargo Maintains Jazz Pharmaceuticals (JAZZ) Overweight Recommendation - MSN
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative - Yahoo Finance
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks - Yahoo Finance
Jazz Pharmaceuticals announces FDA acceptance and Priority Review of supplemental biologics license application for Ziihera - marketscreener.com
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Biotech Powerhouse with a 14.76% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona - msn.com
Universal Beteiligungs und Servicegesellschaft mbH Has $15.32 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Polaris Capital Management LLC Sells 81,000 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Executive Compensation Program 2025: Structure, Philosophy, and Key Features Explained - Minichart
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - 富途牛牛
Jazz Pharmaceuticals (NASDAQ: JAZZ) details 2025 pay, board and pipeline - Stock Titan
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Oncology Data, Cannabis Shift And Modeyso Royalty News - simplywall.st
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):